Terms: = Lymphoma AND CXCR4, D2S201E, 7852, ENSG00000121966, P61073, NPYY3R, NPY3R, HM89, NPYRL, LESTR, HSY3RR, LCR1, fusin, WHIM, NPYR, FB22, CD184
518 results:
1. How to manage waldenström's macroglobulinemia in 2024.
Grunenberg A; Buske C
Cancer Treat Rev; 2024 Apr; 125():102715. PubMed ID: 38471356
[TBL] [Abstract] [Full Text] [Related]
2. cxcr4 whim syndrome is a cancer predisposition condition for virus-induced malignancies.
Moulin C; Beaupain B; Suarez F; Bertrand Y; Beaussant SC; Fischer A; Durin J; Ranta D; Espéli M; Bachelerie F; Bellanné-Chantelot C; Molina T; Emile JF; Balabanian K; Deback C; Donadieu J
Br J Haematol; 2024 Apr; 204(4):1383-1392. PubMed ID: 38442908
[TBL] [Abstract] [Full Text] [Related]
3. A Rare Case of Non-IgM Lymphoplasmacytic lymphoma with Unusual Lack of Immunoglobulin Light Chain Production.
Yin J; Bains A; Alsammak M; Fu JJ
Am J Case Rep; 2024 Mar; 25():e940963. PubMed ID: 38437184
[TBL] [Abstract] [Full Text] [Related]
4. [Research Progress on the Application Strategies of Plerixafor in the Peripheral Blood Stem Cell Mobilization for Autologous Transplantation--Review].
Fang Y; Ye PP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):322-326. PubMed ID: 38387943
[TBL] [Abstract] [Full Text] [Related]
5. [Pathogenesis and Targeted Treatment Progress of Splenomegaly in Primary Myelofibrosis--Review].
Chen ZW; Wang SX; Li F
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):308-312. PubMed ID: 38387940
[TBL] [Abstract] [Full Text] [Related]
6. Thymic-Epithelial-Cell-Dependent Microenvironment Influences Proliferation and Apoptosis of Leukemic Cells.
Patel SK; Zhdanovskaya N; Sergio I; Cardinale A; Rosichini M; Varricchio C; Pace E; Capalbo C; Locatelli F; Macone A; Velardi E; Palermo R; Felli MP
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338689
[TBL] [Abstract] [Full Text] [Related]
7. Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia.
Tam CS; Opat S; D'Sa S; Jurczak W; Lee HP; Cull G; Owen RG; Marlton P; Wahlin BE; García-Sanz R; McCarthy H; Mulligan S; Tedeschi A; Castillo JJ; Czyż J; Fernández De Larrea C; Belada D; Libby E; Matous J; Motta M; Siddiqi T; Tani M; Trněný M; Minnema MC; Buske C; Leblond V; Treon SP; Trotman J; Wu B; Yu Y; Shen Z; Chan WY; Schneider J; Allewelt H; Cohen A; Dimopoulos MA
Blood Adv; 2024 Apr; 8(7):1639-1650. PubMed ID: 38315878
[TBL] [Abstract] [Full Text] [Related]
8. cxcr4-targeted Theranostics in Hematooncology: Opportunities and Challenges.
Werner R; Haug A; Buske C; Heidegger S; Illert AL; Bassermann F; Herhaus P; Buck A; Duell J; Topp MS; Kraus S; Einsele H; Lapa C; Raderer M; Lenz G; Habringer S; von Tresckow B; Keller U
Nuklearmedizin; 2024 Apr; 63(2):57-61. PubMed ID: 38190998
[TBL] [Abstract] [Full Text] [Related]
9. Indolent B-cell lymphoma with t(14;19) investigated from a molecular perspective.
Karrs JX; Sathyanarayana SH; Xu X; Green DC; Kahn WA; Loo EY; Kaur P
J Hematop; 2023 Dec; 16(4):217-221. PubMed ID: 38175432
[TBL] [Abstract] [Full Text] [Related]
10. cxcr4-directed PET/CT with [
Dreher N; Hahner S; Fuß CT; Schlötelburg W; Hartrampf PE; Serfling SE; Schirbel A; Samnick S; Higuchi T; Weich A; Lapa C; Rosenwald A; Buck AK; Kircher S; Werner RA
Eur J Nucl Med Mol Imaging; 2024 Apr; 51(5):1383-1394. PubMed ID: 38082196
[TBL] [Abstract] [Full Text] [Related]
11. C-X-C Motif Chemokine Receptor 4-Targeted Radioligand Therapy in Hematological Malignancies-Myeloablative Effects, Antilymphoma Activity, and Safety Profile.
Dreher N; Dörrler AL; Kraus S; Higuchi T; Serfling SE; Samnick S; Einsele H; Grigoleit GU; Buck AK; Werner RA
Clin Nucl Med; 2024 Feb; 49(2):146-151. PubMed ID: 38081189
[TBL] [Abstract] [Full Text] [Related]
12. EPI-X4, a cxcr4 antagonist inhibits tumor growth in pancreatic cancer and lymphoma models.
Sagini MN; Zepp M; Eyol E; Ali DM; Gromova S; Dahlmann M; Behrens D; Groeschel C; Tischmeier L; Hoffmann J; Berger MR; Forssmann WG
Peptides; 2024 May; 175():171111. PubMed ID: 38036098
[TBL] [Abstract] [Full Text] [Related]
13. Clinical, biological, electrophysiological and therapeutic profile of patients with anti-MAG neuropathy according to MYD88
Guérémy A; Boucraut J; Boudjarane J; Grapperon AM; Fortanier E; Farnault L; Gabert J; Vely F; Lacroix R; Kouton L; Attarian S; Delmont E
J Neurol; 2024 Mar; 271(3):1320-1330. PubMed ID: 37979093
[TBL] [Abstract] [Full Text] [Related]
14. Chemokine receptor-targeted PET/CT provides superior diagnostic performance in newly diagnosed marginal zone lymphoma patients: a head-to-head comparison with [
Kosmala A; Duell J; Schneid S; Serfling SE; Higuchi T; Weich A; Lapa C; Hartrampf PE; Raderer M; Einsele H; Buck AK; Topp MS; Schlötelburg W; Werner RA
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):749-755. PubMed ID: 37943339
[TBL] [Abstract] [Full Text] [Related]
15. Advances in PET Imaging of the cxcr4 Receptor: [
Lindenberg L; Ahlman M; Lin F; Mena E; Choyke P
Semin Nucl Med; 2024 Jan; 54(1):163-170. PubMed ID: 37923671
[TBL] [Abstract] [Full Text] [Related]
16. Canonical BAF complex regulates the oncogenic program in human T-cell acute lymphoblastic leukemia.
Aoki K; Hyuga M; Tarumoto Y; Nishibuchi G; Ueda A; Ochi Y; Sugino S; Mikami T; Kobushi H; Kato I; Akahane K; Inukai T; Takaori-Kondo A; Takita J; Ogawa S; Yusa K
Blood; 2024 Feb; 143(7):604-618. PubMed ID: 37922452
[TBL] [Abstract] [Full Text] [Related]
17. [Regulatory Mechanism of Mangiferin Combined with Bortezomib on Malignant Biological Behavior of Burkitt lymphoma and Its Effect on Expression of CXC Chemokine Receptors].
Yan ZM; Liu YQ; Xu QL; Lin J; Liu X; Zhu QP; Chen XJ; Liu TB; Lian XL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1394-1402. PubMed ID: 37846690
[TBL] [Abstract] [Full Text] [Related]
18. Chemokine Receptor PET/CT Provides Relevant Staging and Management Changes in Marginal Zone lymphoma.
Duell J; Buck AK; Hartrampf PE; Schlötelburg W; Schneid S; Weich A; Dreher N; Lapa C; Kircher M; Higuchi T; Samnick S; Serfling SE; Raderer M; Rasche L; Einsele H; Topp MS; Kosmala A; Werner RA
J Nucl Med; 2023 Dec; 64(12):1889-1894. PubMed ID: 37797975
[TBL] [Abstract] [Full Text] [Related]
19. BM-MSCs display altered gene expression profiles in B-cell acute lymphoblastic leukemia niches and exert pro-proliferative effects via overexpression of IFI6.
Pan C; Hu T; Liu P; Ma D; Cao S; Shang Q; Zhang L; Chen Q; Fang Q; Wang J
J Transl Med; 2023 Sep; 21(1):593. PubMed ID: 37670388
[TBL] [Abstract] [Full Text] [Related]
20. Current approach to Waldenström macroglobulinemia.
Kapoor P; Rajkumar SV
Blood Rev; 2023 Nov; 62():101129. PubMed ID: 37659912
[TBL] [Abstract] [Full Text] [Related]
[Next]
